Driving innovation with Alluvi Research
With a commitment to science, Alluvi Labs delivers rigorously tested peptides and supplements, made solely for regulated research and development.
Alluvi Labs
Designed for scientific accuracy
Alluvi Retatrutide Pre-Filled Pen Review
Alluvi Labs continues to research advanced GLP multi-agonist compounds. This formulation is provided in controlled batches for lab testing of stability, behavior, and injector system function.
Track. Dose. Progress
The Alluvi app supports wellness goals with smart tracking, log nutrition, monitor weight, and stay consistent through a modern mobile dashboard
Recovery Meets Routine
Daily gummy supplements crafted for sleep, stress, support and muscle recovery, for rest and protein for strength, all in a clean and delicious form
Power-up in a Gummy
A delicious way to fuel your body with protein and creatine–Alluvi Gummy bears are a quick, convenient solution to stay on top of daily nutrients. No scoops. No Shakes. Just results
No prep. No hassle. Just precision dosing.
Alluvi pens are supplied ready-to-use – no mixing, no guesswork.
Developed for controlled research applications, each unit features fixed pre-measured volumes to support consistency and reliability during laboratory evaluation.
Not for human or veterinary consumption.
Track Data. Refine Research.
From peptide pens to supplement gummies, Alluvi provides tools that streamline data collection, organized logging, and weekly progress summaries — ensuring reliable assessment within structured research and development settings.
Not intended for human or animal consumption.
Evidence-Based Insights. Driven by Science.
Independent studies have evaluated GLP-1 multi-agonist compounds in controlled laboratory settings.
Alluvi supplies Retatrutide pens strictly for research and development use.
They are not intended for human or veterinary consumption.
All data is sourced from third-party published research and is provided for academic reference only.
Every Alluvi product is distributed exclusively for laboratory research purposes.
22.5%
Average weight reduction observed with Retatrutide.
Data taken from published research on GLP-1 multi-agonist compounds.
Provided strictly for scientific reference.
600
Clinical trial participants reduced daily intake by 600 calories on average.
This reduction occurred naturally, without prescribed dieting.
Linked to lower appetite and stronger satiety signaling.
Shared only for academic context.
28%
Improvement in energy levels was reported during trials.
Figure documented in published GLP-1 multi-agonist studies.
Provided as a scientific reference only.
18.3 kg
Average body weight loss recorded over 48 weeks at high-dose Retatrutide.
Data drawn from peer-reviewed research on GLP-1 multi-agonists.
Alluvi does not market or recommend medical use of its products.
The Alluvi AI App is Coming Soon
Start your free trial soon and see how easy it is to track, manage, and optimize your time.
